The unmet need: why conventional psychiatry is falling short

Depression affects more than 264 million people worldwide, yet a substantial proportion of patients fail to achieve adequate relief from existing pharmacotherapy — a clinical reality that defines treatment-resistant depression (TRD) and has made it one of the most actively pursued targets in contemporary drug development. TRD is formally defined as failure to respond adequately to prior antidepressant therapy, a framing repeated consistently across COMPASS Pathfinder and Cybin UK patent filings and now embedded in regulatory discourse at agencies including the FDA.

PTSD occupies a narrower but increasingly targeted slice of this landscape. GH Research Ireland’s 5-MeO-DMT applications explicitly cite PTSD-associated anhedonia and social and emotional withdrawal as therapeutic targets, while Parow Entheobiosciences frames PTSD alongside OCD and depression as phenotypic disease model endpoints. Together, these two indications represent the primary clinical anchors for the psychedelic-assisted therapy patent wave currently underway.

The scale of unmet need has attracted both commercial biotechs and academic medical centres to file IP. According to WHO, depression is a leading cause of disability globally — context that patent assignees from COMPASS Pathfinder to New York University cite explicitly as commercial and clinical justification for their programmes.

Primary molecular targets driving psychedelic drug design

The 5-HT2A receptor (serotonin receptor subtype 2A) is the dominant molecular target across all retrieved results. Psilocybin is consistently described as a prodrug converted in vivo to psilocin, which exerts its primary therapeutic effects via 5-HT2A agonism — a mechanistic description cited in filings from New York University, Cybin UK, COMPASS Pathfinder, and Universitätsspital Basel.

Beyond acute receptor pharmacology, a neuroplasticity axis has emerged as a secondary mechanistic rationale. Zylorion Health’s filings describe psilocybin and psilocin as stimulators of neurogenesis and neurite outgrowth, identifying neuronal length increase and CNS circuit integration as downstream therapeutic mechanisms in depression and PTSD. This framing — emphasising structural brain changes rather than transient receptor activation — is conceptually aligned with the neuroplasticity literature published by institutions such as NIH-funded researchers.

Two additional mechanistic vectors appear in the dataset. Hadasit Medical Research Services and Ezrath Nashim — The Rabanit Herzog Memorial Hospital filings propose NMDA receptor agonism as a complementary mechanism, citing potential synergy with psychedelics in TRD specifically. Freedom Biosciences has filed patents claiming that PDE9 (phosphodiesterase type 9) inhibitors enhance the efficacy of serotonergic psychedelics while simultaneously reducing their abuse potential — a dual-purpose combination rationale that is mechanistically distinct from any other co-treatment partner in this dataset.

The patent pipeline: five distinct therapeutic modalities

The psychedelic-assisted therapy patent landscape is not monolithic. Five structurally distinct therapeutic modalities are represented in the dataset, each with a different delivery strategy, compound class, and development stage.

1. Direct oral or parenteral psilocybin and psilocin administration

The largest patent cluster covers oral or parenteral administration of psilocybin or psilocin, either as a single macrodose or as a multi-dose regimen. COMPASS Pathfinder’s TRD-specific filings describe administering two or more doses to subjects both responsive and unresponsive to a first dose — a dose-escalation strategy within a therapeutic context. Cybin UK’s parenteral formulation patents describe intravenous or intramuscular delivery of a short-acting psychedelic agent as a single effective parenteral dose, citing randomised double-blind study data showing improvements in depression and anxiety rating scales.

2. Novel analogues — deuterated and prodrug chemistry

Cybin IRL Limited has filed patents on deuterated psilocin for MDD, substance use disorders, anxiety disorders, and headache disorders — a strategy to develop next-generation compounds with potentially modified pharmacokinetic or metabolic profiles. Terran Biosciences has filed on psilocybin HCl and O-acetylpsilocin fumarate as novel salt and solid-state forms, with co-crystal formulations pairing with serotonin receptor modulators such as ketanserin. Zylorion Health has separately filed on crystalline forms A, B, and C of psilocin and psilocybin, explicitly claiming PTSD as an indication.

3. Transdermal micro-dosing delivery

Pike Therapeutics has filed patents on transdermal micro-dosing delivery of psilocybin, psilocin, LSD, and ibogaine derivatives, covering TRD, MDD, OCD, addiction, anxiety, and cluster headaches. The micro-dosing approach is positioned as a sub-perceptual dosing strategy distinct from macrodose psychedelic-assisted sessions. Tryp Therapeutics has separately filed on intravenous infusion methods designed to rapidly induce a dissociative state within 30 minutes and maintain a predetermined plasma concentration throughout a defined therapeutic window, with EEG monitoring proposed for state confirmation.

4. 5-MeO-DMT for PTSD and persistent depressive disorder

GH Research Ireland Limited has filed multiple patents covering intravenous, intramuscular, or subcutaneous administration of 5-MeO-DMT for social and emotional withdrawal and detachment, explicitly including PTSD and persistent depressive disorder as target indications. The filings cite anhedonia reduction measurable within 2 hours of administration and sustained at day 7, day 14, and day 28 endpoints using PID-5 (Personality Inventory for DSM-5) scores. This represents the most PTSD-specific therapeutic signal in the entire dataset.

“GH Research Ireland’s 5-MeO-DMT PTSD filings cite anhedonia reduction measurable within 2 hours of administration and sustained at day 28 — the most PTSD-specific clinical signal in the psychedelic patent dataset.”

5. LSD and mescaline as psychotherapy adjuncts

Universitätsspital Basel has filed multiple patents covering LSD dose identification and optimisation across micro-, mini-, psychedelic, ego-dissolution, and cardiovascular-safe dose tiers, and mescaline as a therapeutic alternative when patients exhibit adverse responses to psilocybin. The LSD filings describe methods for use in generalised anxiety disorder and depression with monitoring of STAI, HDRS, BDI, and SCL-90 rating scales. Both bodies of work are framed as adjuncts to psychotherapy rather than standalone pharmacological treatments.

Combination regimens — the most contested IP battleground

Combination regimen patents represent the densest and most strategically complex cluster in this dataset. At least five distinct combinatorial vectors are currently patented, each with a mechanistic rationale, and no single combination has yet achieved clinical validation sufficient to establish a standard of care.

Psychedelic + SSRI: the primary IP battleground

Two distinct SSRI-combination strategies are patented. COMPASS Pathfinder claims psilocybin co-administered with an adjunctive SSRI for TRD, and separately, benzodiazepine co-administration to restore psilocybin sensitivity in chronic SSRI users. Cybin UK claims short-duration psychedelic plus SSRI combinations. Universitätsspital Basel’s antidepressant-psilocybin patent proposes SSRI pretreatment — specifically escitalopram — to elevate endogenous serotonin prior to 5-HT2A receptor stimulation, thereby enhancing positive psychological outcomes. These filings collectively signal that the SSRI-psychedelic interaction is a major IP battleground with overlapping claims across multiple jurisdictions.

MDMA as an empathogen primer

Universitätsspital Basel’s MDMA plus psychedelic filings propose MDMA as an empathogen and entactogen to prime positive emotional states prior to psychedelic administration, with the mechanism attributed to endogenous monoamine release followed by 5-HT2A stimulation. This combination is specifically designed to reduce anxiety and enhance therapeutic outcomes during the psychedelic session.

Effect termination as safety-by-design IP

Terran Biosciences’ “trip terminator” approach — a delayed-release 5-HT2A antagonist (ketanserin, or atypical antipsychotics including olanzapine, risperidone, and quetiapine) incorporated into the same dosage form as the psychedelic — represents an emerging safety-by-design direction. This strategy could lower barriers to clinical use by enabling controlled cessation of psychedelic effects, and is relevant to regulatory strategy and commercial scalability.

Clinical translation signals and what the evidence actually shows

Clinical translation signals in this dataset are predominantly embedded within patent prior art disclosures rather than as primary academic literature — an important caveat for interpreting the development stage of any specific programme. No retrieved result explicitly reports Phase III trial outcome data, regulatory submission documents, or approved product labelling for psychedelic-assisted therapy in TRD or PTSD.

The strongest clinical signals come from COMPASS Pathfinder’s TRD multi-dose regimen patents, which reference a randomised, double-blind clinical programme as the basis for their filing strategy — language consistent with a Phase II/III trial design. Cybin UK’s combination patents cite a specific double-blind, placebo-controlled crossover clinical trial (ClinicalTrials.gov identifier NCT03912974) investigating psilocybin 25 mg after escitalopram pretreatment, reporting that escitalopram did not reduce the positive mood or mind-altering effects of psilocybin in healthy subjects (Clin Pharmacol Ther. 2022 Apr; 111(4): 886–895).

New York University’s cancer depression and anxiety patent describes a method for alleviating depression and anxiety for at least one year following a single psilocin dose — language consistent with long-duration follow-up clinical observation. GH Research Ireland’s 5-MeO-DMT PTSD filings use structured outcome assessment language — PID-5 scores at 2-hour, day 1, day 7, day 14, and day 28 time points — consistent with IND-enabling or Phase I/II study design.

The sole academic literature retrieved is a naturalistic, observational study from Maastricht University (2022), which reports decreases in state and trait anxiety (STAI scores) in psilocybin-containing truffle ceremony attendees, assessed at baseline, the morning after, and one week post-ceremony. This provides non-controlled human evidence of anxiolytic effects but does not constitute controlled clinical trial data. Standards for clinical evidence in this field are increasingly scrutinised by regulators including the European Medicines Agency.

Strategic implications for drug developers and IP teams

The psychedelic-assisted therapy IP landscape presents both significant opportunity and meaningful navigational complexity for teams entering this space. Four strategic observations emerge directly from the patent data.

COMPASS Pathfinder’s IP fence around TRD

COMPASS Pathfinder has established a broad IP portfolio covering psilocybin polymorphs, TRD dosing regimens, combination with SSRIs, and SSRI washout management via benzodiazepines — creating overlapping IP layers across CA, US, AU, and WO filing families. Parties developing psilocybin for TRD should conduct freedom-to-operate analysis across these families before advancing clinical programmes. The breadth of this portfolio — spanning formulation, indication, dose regimen, and combination strategies — signals a comprehensive IP fence-building strategy of the kind tracked by WIPO‘s patent analytics division.

Novel analogues as a differentiation route

Cybin’s deuterated psilocin and Terran Biosciences’ co-crystal and salt forms signal that chemical entity differentiation — rather than pure use and method patents — may offer stronger IP durability and regulatory data package exclusivity. Drug developers should evaluate whether analogue programmes can demonstrate meaningful pharmacokinetic or efficacy differentiation from natural psilocybin before committing to a development path.

PTSD as the less crowded indication

GH Research Ireland’s 5-MeO-DMT PTSD filings and Parow Entheobiosciences’ phenotypic mouse model work represent the clearest PTSD-specific signals in this dataset. The PTSD IP landscape appears less crowded than TRD, potentially offering earlier freedom-to-operate for programmes specifically targeting this indication — a strategic window that may narrow as more assignees enter the space.

Effect control as a standalone IP and regulatory category

Patents from Terran Biosciences (5-HT2A modulator co-formulations), David Feifel (anxiolytic combinations), and COMPASS Pathfinder (benzodiazepine co-administration) collectively signal that managing the experiential risk profile of psychedelics — rather than only their efficacy — is becoming a distinct IP and clinical development priority. This is directly relevant to regulatory strategy and commercial scalability, particularly in jurisdictions where controlled substance scheduling creates additional barriers.

“The PTSD IP landscape appears less crowded than TRD, potentially offering earlier freedom-to-operate for programmes specifically targeting this indication — a strategic window that may narrow as more assignees enter the space.”